Contact
searchSearch
HMP Global

Biosimilars Topic Center

Featured Article

Conference Coverage
Real-World Strategies for Implementing Biosimilars
04/12/2023
Hannah Musick
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed...
04/12/2023
First Report Managed Care
From First Report Managed Care
Conference Insider
Addressing and Understanding Challenges Linked With Adopting Biosimilars Into Practice
12/08/2020
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear...
12/08/2020
Pharmacy Learning Network
Quiz
Identifying Pharmacist Knowledge of a Medication Drug Type
11/24/2020
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data,...
11/24/2020
Pharmacy Learning Network
News
Most Pharmacists Show Good Grasp of Biosimilar Medications, Study Finds
11/20/2020
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug...
11/20/2020
Pharmacy Learning Network
Newsfeed
Biosimilar Infliximab Appears Effective in Crohn`s Disease
12/11/2018
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears...
12/11/2018
Pharmacy Learning Network
News
Etanercept Biosimilar is Effective, Well-Tolerated for Rheumatoid Arthritis
02/16/2018
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the...
02/16/2018
Pharmacy Learning Network
News
Biosimilar Infliximab Appears Safe, Effective in IBD Patients
12/15/2017
Researchers examined the effectiveness of switching to a biosimilar version of a drug in patients with IBD. 
Researchers examined the effectiveness of switching to a biosimilar version of a drug in patients with IBD. 
Researchers examined the...
12/15/2017
Pharmacy Learning Network
News
Pharmacist Role in Promoting Proper Biosimilar Usage
12/14/2017
Evelyn Hermes-Desantis, PharmD, BCPS, recently discussed the many factors involved in managing biosimilars in the hospital setting and the role pharmacists play in promoting their appropriate use in the context of safe patient care.
Evelyn Hermes-Desantis, PharmD, BCPS, recently discussed the many factors involved in managing biosimilars in the hospital setting and the role pharmacists play in promoting their appropriate use in the context of safe patient care.
Evelyn Hermes-Desantis, PharmD,...
12/14/2017
Pharmacy Learning Network
News
FDA Approves Another Biosimilar for RA Drug
12/14/2017
The FDA has approved a biosimilar for multiple autoimmune diseases. 
The FDA has approved a biosimilar for multiple autoimmune diseases. 
The FDA has approved a...
12/14/2017
Pharmacy Learning Network
News
FDA Approves First Biosimilar for Breast, Stomach Cancer
12/01/2017
The FDA has approved a biosimilar for two types of cancer.
The FDA has approved a biosimilar for two types of cancer.
The FDA has approved a...
12/01/2017
Pharmacy Learning Network
News
The Challenges of Bringing Biosimilars to Market
11/21/2017
Edward Li, Pharm D, MPH, BCOP, a professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy, explains how industry experts can help bring biosimilars to the market faster.
Edward Li, Pharm D, MPH, BCOP, a professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy, explains how industry experts can help bring biosimilars to the market faster.
Edward Li, Pharm D, MPH, BCOP, a...
11/21/2017
Pharmacy Learning Network

Newsfeed

News
Communication Needed to Improve Biosimilar Transition, Adherence
10/19/2017
Patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from an originator treatment to a biosimilar stopped taking the biosimilar medication within 6 months, a study showed. 
Patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from an originator treatment to a biosimilar stopped taking the biosimilar medication within 6 months, a study showed. 
Patients with rheumatoid...
10/19/2017
Pharmacy Learning Network
News
FDA Approves Amgen`s Cheaper Copy of Arthritis Drug Humira
09/23/2016
The FDA has approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.
The FDA has approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.
The FDA has approved a cheaper,...
09/23/2016
Pharmacy Learning Network
News
Novartis Biosimilar Takes Aim at Amgen`s Enbrel
10/23/2015
The FDA has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said.
The FDA has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said.
The FDA has accepted Novartis...
10/23/2015
Pharmacy Learning Network
News
FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names
08/28/2015
The FDA proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts.
The FDA proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts.
The FDA proposed on Thursday...
08/28/2015
Pharmacy Learning Network
News
MG217 Treatment Cream and Skin Protectant Recalled Due to Staphylococcus Aureus Contamination
06/04/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for MG217 multisymptom treatment cream and skin protectant due to microbial contamination of staphylococcus aureus, affecting 690 tubes.
The US Food and Drug Administration (FDA) has issued a Class I recall for MG217 multisymptom treatment cream and skin protectant due to microbial contamination of staphylococcus aureus, affecting 690 tubes.
The US Food and Drug...
06/04/2026
Pharmacy Learning Network
News
Pred Mild Eye Drops Recalled Due to Failed Stability Specifications
06/04/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for Pred Mild, prednisolone acetate ophthalmic suspension, due to failed stability specifications, affecting 2736 bottles.
The US Food and Drug Administration (FDA) has issued a Class III recall for Pred Mild, prednisolone acetate ophthalmic suspension, due to failed stability specifications, affecting 2736 bottles.
The US Food and Drug...
06/04/2026
Pharmacy Learning Network
News
Nicotine Transdermal System Patches Recalled Due to Failed Impurities/Degradation Specifications
06/04/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for nicotine transdermal system patches, 14mg, due to the product’s failure to meet impurities/degradation specifications, affecting 59 808 pouches.
The US Food and Drug Administration (FDA) has issued a Class III recall for nicotine transdermal system patches, 14mg, due to the product’s failure to meet impurities/degradation specifications, affecting 59 808 pouches.
The US Food and Drug...
06/04/2026
Pharmacy Learning Network
News
Busulfan Injections Recalled Due to Failed Impurities/Degradation Specifications
05/28/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for busulfan injections, 60mg per 10mL (6mg per mL) due to the presence of particulate matter, affecting 9528 vials.
The US Food and Drug Administration (FDA) has issued a Class III recall for busulfan injections, 60mg per 10mL (6mg per mL) due to the presence of particulate matter, affecting 9528 vials.
The US Food and Drug...
05/28/2026
Pharmacy Learning Network
News
Liraglutide Injections Recalled Due to the Presence of Particulate Matter
05/28/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for liraglutide injections, 18mg/3mL (6mg/mL) due to the presence of particulate matter, affecting 217 621 pen injectors.
The US Food and Drug Administration (FDA) has issued a Class II recall for liraglutide injections, 18mg/3mL (6mg/mL) due to the presence of particulate matter, affecting 217 621 pen injectors.
The US Food and Drug...
05/28/2026
Pharmacy Learning Network
News
Atomoxetine Capsules Recalled Due to a Labeling Error
05/28/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for atomoxetine capsules HCL, 10mg due to a labeling mix-up, affecting 149 capsules.
The US Food and Drug Administration (FDA) has issued a Class II recall for atomoxetine capsules HCL, 10mg due to a labeling mix-up, affecting 149 capsules.
The US Food and Drug...
05/28/2026
Pharmacy Learning Network
PharmLaw
CVS Challenges Tennessee Law Restricting PBM Ownership of Pharmacies
05/27/2026
Hannah Musick
CVS Health has sued the Tennessee state legislature over a new law barring pharmacy benefit managers (PBMs) from owning pharmacies, setting up a potentially significant legal battle over state authority to regulate vertically integrated...
CVS Health has sued the Tennessee state legislature over a new law barring pharmacy benefit managers (PBMs) from owning pharmacies, setting up a potentially significant legal battle over state authority to regulate vertically integrated...
CVS Health has sued the...
05/27/2026
Pharmacy Learning Network
News
Lactated Ringer’s Injections Recalled Due to the Presence of Particulate Matter
05/21/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall on Lactated Ringer’s injections USP, 1000 mL due to the presence of particulate matter, affecting 95 412 containers.
The US Food and Drug Administration (FDA) has issued a Class I recall on Lactated Ringer’s injections USP, 1000 mL due to the presence of particulate matter, affecting 95 412 containers.
The US Food and Drug...
05/21/2026
Pharmacy Learning Network
News
Preservative-Free Lubricant Eye Drops Recalled Due to Lack of Sterility Assurance
05/21/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall on Oasis Tears PF, preservative-free lubricant eye drops, due to the lack of assurance of sterility.
The US Food and Drug Administration (FDA) has issued a Class II recall on Oasis Tears PF, preservative-free lubricant eye drops, due to the lack of assurance of sterility.
The US Food and Drug...
05/21/2026
Pharmacy Learning Network
News
Buprenorphine Hydrochloride Injections Recalled Due to the Presence of Particulate Matter
05/21/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for buprenorphine hydrochloride injections due to the presence of particulate matter, which has been identified as buprenorphine base matter.
The US Food and Drug Administration (FDA) has issued a Class II recall for buprenorphine hydrochloride injections due to the presence of particulate matter, which has been identified as buprenorphine base matter.
The US Food and Drug...
05/21/2026
Pharmacy Learning Network

Insights

Interactive Features

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use